Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303688 | 1.00 | GAA (0.61) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL9958801 | 0.96 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL28065008 | 0.96 | GAA (0.56) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL472723 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL3777425 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6138788 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL3442509 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6138705 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6138989 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6138882 | 0.94 | HAO1 (0.55) | GAAMGAMSIMGAM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2006-07-06 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | RPP30, INO80, CDK20 | GAA 4434/4885MGAM 4209/4885SI 4673/4885 |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | GAA 2597/4885MGAM 4380/4885SI 3539/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | GAA 4408/4885MGAM 3989/4885SI 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.